Drug Library Category

ISO 17025–ACCREDITED LABORATORY ENVIRONMENT

Oncology and Targeted Anticancer Drugs DMPK and Bioanalytical Services

Creative Proteomics provides DMPK, bioanalytical, metabolite profiling, and biomarker-related support for oncology and targeted anticancer drug research. This section of our drug library helps researchers explore analytical service options for cytotoxic chemotherapy agents, small-molecule targeted therapies, biologics, antibody-drug conjugates, targeted protein degraders, and other novel anticancer therapeutics.

Oncology drug studies often require more than systemic parent-drug exposure. Depending on modality and study design, researchers may need to evaluate active metabolites, tumor tissue exposure, intracellular drug levels, payload release, target-pathway modulation, resistance-associated biomarkers, or exposure-response relationships in complex models.

Explore Oncology Drug Classes Discuss Your Study

Modality-Aware EntryStart from cytotoxic agents, targeted small molecules, biologics, ADCs, or degraders.

Tumor Exposure LogicConnect plasma, tissue, intracellular, and payload-level measurements.

Mechanism-Linked ReadoutsAlign exposure data with pathway, apoptosis, proliferation, or resistance biomarkers.

Oncology Study Logic

🎯

Drug Class / ModalityCytotoxic agents, targeted therapies, biologics, ADCs, degraders

🧪

Analytes & PayloadsParent drug, active metabolites, released payloads, linker-related species

📈

PK / Tissue ExposurePlasma, tumor tissue, organ distribution, intracellular accumulation

🧬

Pathway & ResponseTarget modulation, apoptosis, proliferation, DNA damage, resistance markers

Explore Subcategories

Navigate Oncology and Targeted Anticancer Drug Classes

Use these entry points to move from the broad oncology category into more specific therapeutic formats and analytical support pages.

⚗️

Cytotoxic Chemotherapy Agents

Support for traditional cytotoxic agents where studies may involve parent-drug quantification, active metabolite profiling, DNA-reactive product analysis, tissue exposure, intracellular accumulation, or stability-aware method development.

Alkylating AgentsPlatinum CompoundsAntimetabolitesTopoisomerase Inhibitors

Explore Cytotoxic Chemotherapy →

🎯

Small-Molecule Targeted Therapies

Analytical support for kinase inhibitors and pathway-directed small molecules where CYP metabolism, transporter effects, tumor exposure, and resistance-linked readouts can affect study interpretation.

TKIsCDK InhibitorsPI3K / mTOR InhibitorsPARP Inhibitors

Explore Targeted Therapies →

🧬

Biologics and Novel Therapeutics

Modality-aware workflows for biologics, ADCs, fusion proteins, degraders, and emerging anticancer formats that may require payload, linker, target engagement, and biomarker-related analysis.

mAbsADCsFusion ProteinsTargeted Degraders

Explore Biologics & Novel Therapeutics →

Common Research Questions

What Oncology Researchers Need to Resolve

Oncology DMPK projects often start with a modality-specific analytical question. These questions determine whether the workflow should focus on targeted quantification, tissue exposure, MetID, payload analysis, stability, or mechanism-linked biomarkers.

Parent drug enough?Is systemic parent-drug exposure sufficient, or should active metabolites, released payloads, intracellular forms, or tissue distribution also be measured?

Which analyte set?Should the assay include metabolites, degradation products, conjugated species, payloads, linker-related products, or endogenous response markers?

Tumor exposure needed?Does the study require tumor homogenate, target-organ, cell lysate, or intracellular concentration data beyond plasma PK?

Metabolism or resistance?Do CYP-mediated metabolism, transporter effects, active metabolites, or resistance-associated changes influence interpretation?

Payload or linker stability?For ADCs and related formats, should released payload, linker stability, conjugated species, or degradation products be tracked?

Biomarker-linked response?Are pathway inhibition markers, apoptosis, proliferation, DNA damage, immune activation, or resistance biomarkers needed alongside exposure data?

Exposure • Mechanism • Response

Connecting Drug Exposure with Oncology Mechanism and Response

Measuring parent-drug concentration is only one part of an oncology study. Researchers may also need to understand whether exposure is associated with target modulation, tumor pathway inhibition, DNA damage, apoptosis, immune activation, or resistance-linked molecular changes.

Exposure LayerParent drug, active metabolites, released payloads, tumor tissue concentration, intracellular accumulation

→

Mechanism LayerDNA crosslinking, nucleotide synthesis, microtubule disruption, kinase pathway modulation, targeted degradation

Modality ContextCytotoxic agent, targeted small molecule, ADC, monoclonal antibody, fusion protein, or degrader

→

Response LayerApoptosis, proliferation, DNA damage, pathway suppression, immune-response or resistance markers

Analytical NeedLC-MS/MS quantification, HRMS MetID, payload analysis, stability profiling, biomarker panels

→

Study InterpretationExposure-response context, tumor distribution, mechanism-linked readouts, PK/PD support

Oncology-specific value: the analytical question is often not just “how much drug is present,” but whether the measured exposure aligns with tumor access, active molecular species, target-pathway modulation, and response-linked readouts.

Example Oncology Contexts and Readouts

Research Focus	Potential Readouts
Cytotoxic exposure interpretation	Parent-drug concentration, active metabolites, DNA damage markers, apoptosis-related readouts
Kinase inhibitor research	Parent/metabolite exposure, pathway inhibition markers, transporter effects, resistance-associated readouts
Tumor tissue distribution	Tumor homogenate concentration, tissue-to-plasma comparison, local exposure assessment
ADC-related workflows	Released payload, linker stability, conjugated and unconjugated species, target-response indicators
Targeted protein degradation	Parent compound, degrader-related metabolites, target protein abundance, downstream pathway markers

Bioanalytical and DMPK Service Capabilities

Service Modules for Oncology Drug Studies

These service modules connect oncology research questions with analytical routes for parent compounds, active metabolites, tissue exposure, payloads, biotransformation products, and stability-related interpretation.

Parent Drug, Metabolite, and Payload Quantification

Targeted quantification of anticancer parent drugs, active metabolites, degradation products, released payloads, and related analytes in biological matrices.

Parent-drug concentration measurement
Active or inactive metabolite quantification
Released payload quantification
Multi-analyte assay development

LC-MS/MS Quantification Parent-Metabolite Panels

PK, Tissue Exposure, and Distribution Assessment

Exposure analysis beyond plasma for studies where tumor, organ, or cellular context is important.

Plasma and serum PK analysis
Tumor tissue exposure assessment
Tissue-to-plasma comparison
Intracellular drug or metabolite analysis

Plasma & Serum Quantification Tissue & Cell Lysate Analysis

Metabolite Identification and Biotransformation Profiling

Clarify how oncology drugs are transformed, cleared, activated, or degraded in biological systems.

Phase I / II metabolite support
CYP-related metabolite profiling
Active metabolite confirmation
Suspected or unknown metabolite screening

Metabolite Identification Phase I / II Metabolites

Stability, Degradation, and Complex Modality Support

Custom workflows for unstable, reactive, linker-based, payload-containing, or structurally complex anticancer therapeutics.

Stability-aware method development
Degradation product profiling
Linker and payload-related workflows
Support for ADCs, degraders, and novel formats

Forced Degradation Custom LC-MS/MS Method

Integrated Analysis

Why Oncology Drug Studies Require Integrated Analysis

Oncology therapeutics differ widely in modality, mechanism, matrix behavior, and response endpoints. A useful analytical workflow should align the drug format with the right analytes, exposure context, and mechanism-linked outputs.

From oncology modality to study-ready workflow

🎯

Drug class or modalityCytotoxic chemotherapy agent, kinase inhibitor, ADC, biologic, degrader, or proprietary anticancer format.

🧪

Relevant analyte setParent drug, active metabolite, payload, linker-related species, degradation product, pathway biomarker, or endogenous response marker.

📍

Matrix and exposure contextPlasma, serum, tumor tissue, organ homogenate, cell lysate, intracellular extract, or model-specific matrix.

📊

Analytical outputQuantitative exposure data, tissue distribution, MetID findings, stability insight, payload information, or biomarker-linked interpretation.

Cytotoxic agents

Often require active metabolite measurement, DNA-reactive product context, intracellular exposure, stability-aware analysis, or tissue-linked interpretation.

Targeted therapies

Frequently involve CYP metabolism, transporter effects, tumor exposure, pathway inhibition markers, and resistance-associated molecular readouts.

ADCs and biologics

May require released payload quantification, linker stability assessment, target-response indicators, and modality-specific biomarker workflows.

Novel therapeutics

Targeted degraders and emerging formats can require custom assays that combine parent compound, metabolites, target protein abundance, and downstream response markers.

How Creative Proteomics uses this framework

This page serves as the main entry point for oncology and targeted anticancer drug-related DMPK and bioanalytical services, helping researchers move from broad therapeutic category to class-specific analytical strategy.

Project Inquiry

Need Support for a Specific Oncology or Targeted Anticancer Drug?

If your target oncology drug, targeted therapy, biologic, ADC, investigational compound, metabolite, payload, degradation product, or related analyte is not listed, Creative Proteomics can help develop a customized analytical strategy based on your study objective. Share your target analytes, sample matrix, expected concentration range, and required workflow.

Ready to Quantify Your Lead Compound or Metabolite?

Share your matrix type, sample count, and expected range—feasibility routing will confirm whether direct quantification is fit-for-purpose or method development is recommended.

Want to browse compounds, matrices, and assay coverage? Explore the Library →